What 4 Analyst Ratings Have To Say About Spruce Biosciences
Portfolio Pulse from Benzinga Insights
Over the past quarter, Spruce Biosciences (NASDAQ:SPRB) received 4 analyst ratings, with 2 being bullish and 2 somewhat bullish. There were no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target for SPRB is $9.25, with a high of $10.00 and a low of $8.00. This target has increased by 208.33% over the past month. Analyst ratings are based on future earnings predictions and company risk assessments, and are updated quarterly or after major company events.
November 20, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences has received positive ratings from analysts, with an average price target of $9.25, indicating a bullish sentiment. The target represents a significant increase from previous estimates.
The unanimous positive ratings from analysts, combined with a substantial increase in the average price target, suggest a strong bullish sentiment for SPRB in the short term. The confidence score is high due to the recent update and the significant increase in the price target, which may influence investor expectations and stock performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100